Delving into the Latest Updates on 68Ga-citrate with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms-

Target-

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsInfectious DiseasesCongenital Disorders+ [4]

Active Indication-

Inactive Indication

GliomaHepatocellular CarcinomaInflammation+ [2]

Originator Organization-

Active Organization-

Inactive Organization

University Hospital Ltd.

Rutgers State University of New Jersey

The University of California, San Francisco

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Start Date26 Feb 2019

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NCT04139395

/ WithdrawnPhase 3IIT

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

This is a Phase III study to evaluate 68Ga Citrate PET/MRI for detection of origin of fever of unknown origin.

Start Date15 Jan 2019

Sponsor / Collaborator

Stanford University

NCT03116945

/ Unknown statusPhase 2IIT

68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma

The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.

Start Date01 Jun 2016

Sponsor / Collaborator

Rutgers State University of New Jersey

[+1]

100 Clinical Results associated with 68Ga-citrate

Login to view more data

100 Translational Medicine associated with 68Ga-citrate

Login to view more data

100 Patents (Medical) associated with 68Ga-citrate

Login to view more data

6

Literatures (Medical) associated with 68Ga-citrate

10 Dec 2024·Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG

Diagnostic yield of a novel tracer 68Ga-citrate in sarcoidosis patients.

Article

Author: Yanardag, Halil ; Kubat, Bahar ; Bilir, Muammer ; Tetikkurt, Cuneyt ; Sayman, Haluk Burcak

BACKGROUNDSarcoidosis is a granulomatous disease of unknown origin. Conventional laboratory and imaging modalities may lead to equivocal conclusions for sarcoidosis diagnosis. 68Ga-citrate PET/CT has been utilized in the diagnosis of inflammatory and infectious diseases due to its beter performance. Aims: This study was designed to determine the clinical trenchancy of 68Ga-citrate in sarcoidosis patients as an alternative tracer that binds to the somtastotin receptors of the inflammatory cells in sarcoid granulomas because current laboratory modalities may occasionally lack accuracy for sarcoidosis diagnosis. Conventional criteria including clinical, laboratory, radiologic modalities, and 18F-FDG PET/CT were compared with the 68Ga-citrate PET/CT to evaluate the diagnostic yield in sarcoidosis.METHODSForty-four sarcoidosis patients were include in the study. Conventional laboratory and imaging modalities were done in 44 while 68Ga-citrate PET/CT and 18F-FDG-PET/CT were performed in 22 patients. The three modalities were compared with in regard to granulomatous activity evaluation, extrapulmonary organ involvement, and identification of coexistent malignant disease.RESULTS68Ga-citrate PET/CT revealed a significantly higher diagnostic yield for sarcoidosis compared to conventional laboratory and 18F-FDG-PET/CT imaging modalties. 68Ga-citrate PET/CT revealed 72.7% sensitivity and 68.4% specificity for the detection of granulomatous inflammation in sarcoidosis.CONCLUSIONS68Ga-citrate PET/CT was conclusive for activity assessment in sarcoidosis for diagnosis, activity assessment, and identification of extrapulmonary organ involvement. As an innovative novel tracer, 68Ga-citrate identified disease activity, extrapulmonary organ involvement, biopsy sites, and coexistent malignancy due to its chemical properties with a higher statistical diagnostic yield compared to conventional laboratory findings and the PET/CT imaging manifestations in sarcoidosis.

14 May 2018·Current Pharmaceutical DesignQ4 · MEDICINE

Past and Future of Ga-citrate for Infection and Inflammation Imaging

Q4 · MEDICINE

Review

Author: Vorster, Mariza ; Sathekge, Mike ; Saad, Ziauddin ; Buscombe, John

Both 67Ga and 68Ga-citrates are used to detect a wide spectrum of pathology consisting of various inflammatory, infectious and malignant conditions. Considering the now widespread availability and constantly increasing demand for PET/CT studies,68Ga-citrate is gaining ground in clinical settings and the added value of combined metabolic and anatomical imaging achieved by combining PET with Computed Tomography (CT) to PET/CT makes 68Ga-citrate particularly promising. Despite the tracer's non-specificity, it has demonstrated potential especially in the evaluation of various infectious and inflammatory skeletal- and lung conditions. In this review, we will focus on the indications and lessons learned from 67Ga, and present the current status for the use of 68Ga-citrate PET/CT in selected inflammation and infectious diseases based on the limited literature available.

01 Sep 2017·Molecular Cancer ResearchQ2 · MEDICINE

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer

Q2 · MEDICINE

Article

Author: Small, Eric J. ; Ranatunga, Nimna ; Wei, Junnian ; Behr, Spencer C. ; Paris, Pamela L. ; Youngren, Jack ; Truillet, Charles ; Evans, Michael J. ; Aggarwal, Rahul ; Chang, Emily ; Gao, Kenneth T. ; Hann, Byron ; Huang, Jiaoti ; Premasekharan, Gayatri ; Parker, Matthew F.L. ; Ryan, Charles J. ; Huynh, Loc T.

AbstractNoninvasive biomarkers that detect the activity of important oncogenic drivers could significantly improve cancer diagnosis and management of treatment. The goal of this study was to determine whether 68Ga-citrate (which avidly binds to circulating transferrin) can detect MYC-positive prostate cancer tumors, as the transferrin receptor is a direct MYC target gene. PET imaging paired with 68Ga-citrate and molecular analysis of preclinical models, human cell-free DNA (cfDNA), and clinical biopsies were conducted to determine whether 68Ga-citrate can detect MYC-positive prostate cancer. Importantly, 68Ga-citrate detected human prostate cancer models in a MYC-dependent fashion. In patients with castration-resistant prostate cancer, analysis of cfDNA revealed that all patients with 68Ga-citrate avid tumors had a gain of at least one MYC copy number. Moreover, biopsy of two PET avid metastases showed molecular or histologic features characteristic of MYC hyperactivity. These data demonstrate that 68Ga-citrate targets prostate cancer tumors with MYC hyperactivity. A larger prospective study is ongoing to demonstrate the specificity of 68Ga-citrate for tumors with hyperactive MYC.Implications: Noninvasive measurement of MYC activity with quantitative imaging modalities could substantially increase our understanding of the role of MYC signaling in clinical settings for which invasive techniques are challenging to implement or do not characterize the biology of all tumors in a patient. Moreover, measuring MYC activity noninvasively opens the opportunity to study changes in MYC signaling in patients under targeted therapeutic conditions thought to indirectly inhibit MYC. Mol Cancer Res; 15(9); 1221–9. ©2017 AACR.

100 Deals associated with 68Ga-citrate

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 2	FR	University Hospital Ltd.	30 Sep 2021
Juvenile Polyposis Syndrome	Phase 2	FR	University Hospital Ltd.	30 Sep 2021
Prosthetic joint infection	Phase 2	FR	University Hospital Ltd.	30 Sep 2021
Glioma	Phase 2	US	The University of California, San Francisco	26 Feb 2019
Hepatocellular Carcinoma	Phase 2	US	Rutgers State University of New Jersey	01 Jun 2016